Celgene's Revlimid combo OK'd for certain lymphomas
Tuesday, May 28, 2019 12:00 AM
Officials with the FDA today approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product (R2) for the treatment of adult patients with previously-treated follicular lymphoma (FL) or marginal zone lymphoma (MZL), according to a press release.
 
R2 previously received Priority Review designation from the FDA. With this approval, this is the first combination regimen for patients with these indolent forms of non-Hodgkin lymphoma (NHL) that does not include chemotherapy. Indolent lymphomas, which account for approximately 40% of all NHL cases, are slow-growing forms of the disease, which can often be asymptomatic or have fewer symptoms upon diagnosis. Most patients with indolent forms of NHL will relapse or become refractory to their current treatment, according to Celgene.
Read more...
 
ArunA Bio to Provide Corporate Update and Participate on a Panel at the 2019 BIO International Convention
Wednesday, May 22, 2019 05:43 PM

-- Panel Discussion Will Highlight Impact of Exosomes as Therapeutics and Drug Delivery Vehicles --

Athens, GA—May 22, 2019—ArunA Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced that Dr. Mark A. Sirgo, Chief Executive Officer, will lead a corporate presentation at the 2019 BIO International Convention occurring June 3-6, 2019 in Philadelphia, PA. Dr. Sirgo will provide an update on the company’s emerging pipeline and proprietary neural exosome drug delivery capabilities.

In addition, Dr. Steven Stice, Co-Founder and Chief Scientific Officer, will participate on a panel entitled “Harnessing the Potential of Exosomes”. The panel will explore the full potential of exosomes, and Dr. Stice will discuss the use of exosomes as both a therapeutic and a drug delivery vehicle.

Read more...
 
FDA OKs extended use of Takeda's Gattex
Friday, May 17, 2019 12:00 AM

Officials with the FDA have approved extending the indication of Takeda Pharmaceuticals’ teduglutide (Gattex) for injection to pediatric patients age 1 year and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding, according to the drug manufacturer.

Children with SBS are unable to absorb enough nutrients and fluids from what they eat and drink alone. A goal of SBS treatment is to restore the patient’s ability to absorb nutrients and reduce long-term dependence on parenteral support (PS).

“As a pediatric gastroenterologist, one of my main treatment goals for children with SBS is to reduce their dependency on parenteral support,” said Beth Carter, MD, Medical Director of Intestinal Rehabilitation and Nutrition Support, Children’s Hospital Los Angeles, in a prepared statement. “I’m pleased that patients have access to a medication that may help them reach that goal.”

Read more...
 
Celgene's lenalidomide recommended by NICE for multiple myeloma
Friday, May 17, 2019 12:00 AM

An immunomodulator drug to fight multiple myeloma should be available for more patients on the NHS in England and Wales, the National Institute for Health and Care Excellence (NICE) announced today.

Lenalidomide (Revlimid, Celgene) could soon be offered to patients with this form of plasma cell cancer as a first- and second-line drug, it said.

Read more...
 
New Georgia Research Alliance report shows $6B economic impact
Thursday, May 16, 2019 02:47 PM

The Georgia Research Alliance (GRA) has used $649 million in state tax dollars to generate $6 billion in federal money and private investment, the Atlanta-based nonprofit reported Thursday.

The numbers come from an 11-page report put together after freshman Gov. Brian Kemp asked GRA officials to document its impact on the state economy.

Launched in 1990 during the administration of the late Gov. Zell Miller to grow Georgia's technology industry, the GRA budget has shrunk under recent governors. However, the fiscal 2020 spending plan the General Assembly adopted this year holds its funding steady at about $5.1 million.

Read more...
 
<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 3 of 49